PRGO (perrigo.com) Market Value to Book Value Ratio

Official company branding of Perrigo Company PLC (PRGO)

Perrigo Company plc (PRGO) management is currently restructuring the business, pivoting toward health products. This strategy involves divesting non-core units and optimizing the logistics of baby formula. The production cycle relies on external raw material suppliers while maintaining in-house facilities, and the current figure stands at 0.86. Historical price action on the GURU.Markets platform clearly demonstrates the market reaction to these changes.

PRGO Perrigo Corp: Market Value to Book Value in the range 07/04/2022 - 10/27/2026
Original product of Perrigo Company

To stress-test assets, an investor evaluates the Market-to-Book ratio, which measures the market premium over net equity to determine the extent to which a business is overvalued or undervalued. In the context of the large-scale wholesale distribution of over-the-counter medications and baby food by Perrigo Company plc (PRGO), the dynamics of the market value to book value ratio provide a real-time assessment of market confidence in the efficiency of this business model.

Main competitors

Market Value to Book Value Ratio HLN|KVUE (kenvue.com) - Market-to-Book Ratio|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio ALVO (Alvotech)|liquidia.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Galapagos (GLPG)|ANIP: Market Value to Book Value|MNKD (MannKind Corp.) - Market Value to Book Value Ratio|Amphastar Corp (AMPH) - Market Cap to Net Assets Ratio|PCRX (Pacira BioSciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ars-pharma.com (SPRY)|Theravance Biopharma, Inc. (TBPH) - Market Cap to Net Assets Ratio|Market Value to Book Value AQST (Aquestive Therapeutics Inc)|SCPH: Market Value to Book Value Ratio|TECX - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tonix Pharmaceuticals TNXP|SXTC - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio eupraxiapharma.com EPRX|BioHarvest Sciences, Inc. (BHST) - Market Value to Book Value|Market Capitalization to Book Value Ratio EXOZ (Invizyne Technologies, Inc.)|Market-to-Book Ratio ORMP|Entera Bio Ltd. (ENTX) - Market Value to Book Value Ratio|Market Value to Book Value HYFT (ipatherapeutics.com)|ABVC BioPharma, Inc. (ABVC) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Cumberland Pharmaceuticals Inc CPIX|QNTM (Quantum BioPharma Limited) - Market Capitalization to Book Value Ratio|FGEN: Market-to-Book Ratio|Market Value to Book Value Ratio Telomir Pharmaceuticals TELO|RANI (Rani Therapeutics Holdings, Inc.) - Market Value to Book Value|SNYR - Market Value to Book Value Ratio|Market Value to Book Value Rallybio Corp.|LEXX (Lexaria Bioscience) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Pulmatrix Corporation (PULM)|PTHL (Pheton Holdings) - Market Capitalization to Book Value Ratio|Aptorum Group Ltd - Market Value to Equity Ratio|LYRA (Lyra Therapeutics) - Market Value to Book Value Ratio|impactbiomedinc.com (IBO) - Market-to-Book Ratio|Market Cap to Net Assets Ratio tnfpharma.com TNFA|cbdMD (YCBD) - Market Value to Book Value|Market Capitalization to Book Value Ratio PRFX|Market Cap to Net Assets Ratio CYTO|Lipella Pharmaceuticals, Inc. - Market Value to Book Value Ratio|Market-to-Book Ratio OPTN (OptiNose Inc)|Pieris - Market Value to Book Value Ratio|Procaps Group Corp - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Petros Pharmaceuticals|QLI - Market Capitalization to Net Assets|SLRN: Market Capitalization to Book Value Ratio|TFFP (TFF Pharmaceuticals Inc.) - Market Capitalization to Book Value Ratio